Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II sorafenib in renal cancer patients with von Hippel-Lindau syndrome
2007-002132-29Phase 2Terminated
- Sponsor
- Oxford University Hospitals
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in renal cell carcinoma (RCC), von Hippel–Lindau disease (VHL), retinal haemangioma and 1 more, sponsored by Oxford University Hospitals. Started Feb 2008; status: terminated.
02
Drugs
sorafenib
03
Conditions
renal cell carcinoma (RCC)von Hippel–Lindau disease (VHL)retinal haemangiomaHaemangioblastoma
Beyond the preview
Go deeper on 2007-002132-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002132-29.